ATP5G1 Antibody

What exactly is ATP5G1 and how does it function in mitochondrial ATP production?

ATP5G1 is one of three nuclear-encoded genes (along with ATP5G2 and ATP5G3) that encode subunit c of the proton channel in the mitochondrial ATP synthase F0 complex. Mitochondrial ATP synthase consists of two linked multi-subunit complexes: the soluble catalytic core (F1) and the membrane-spanning component (F0) comprising the proton channel . The F1 catalytic portion consists of 5 distinct subunits (alpha, beta, gamma, delta, and epsilon), while the F0 proton channel has nine subunits including ATP5G1 .

ATP5G1 plays a critical role in oxidative phosphorylation by forming part of the channel through which protons flow, utilizing an electrochemical gradient across the inner mitochondrial membrane to catalyze ATP synthesis . While ATP5G1, ATP5G2, and ATP5G3 have distinct mitochondrial import sequences, they encode identical mature proteins, suggesting differential regulation despite similar final functions .

Methodologically, when investigating ATP5G1 function, researchers should consider that manipulating ATP5G1 expression can affect mitochondrial morphology, spare respiratory capacity, and cellular resistance to metabolic stressors as demonstrated in studies of the Arctic ground squirrel (AGS) variant .

How should researchers approach ATP5G1 detection in various experimental contexts?

For optimal ATP5G1 detection, researchers should select antibodies based on the specific application and species being studied:

Western Blot Applications:

• When detecting ATP5G1 in human, mouse, or rat samples, polyclonal antibodies typically work at dilutions of 1:500-1:2000 .

• Monoclonal antibodies provide higher specificity and work effectively at dilutions of 1:2000-1:10000 for Western blotting .

• The observed molecular weight of ATP5G1 is approximately 8 kDa, while the calculated molecular weight is 14 kDa . This discrepancy should be considered when interpreting results.

Immunofluorescence/Immunocytochemistry:

• For subcellular localization studies, use dilutions of 1:50-1:200 .

• Mitochondrial co-localization markers should be employed to confirm proper targeting of ATP5G1 to mitochondria .

Validation approaches:

• Positive controls should include tissues with high mitochondrial content (heart, liver) .

• Knockdown or knockout experiments can confirm antibody specificity.

• When detecting the effect of genetic variants, appropriate amino acid substitutions should be validated with sequencing .

What are the key differences in expression patterns among ATP5G1, ATP5G2, and ATP5G3?

Understanding the differential expression of ATP5G isoforms is critical for experimental design:

• In both mouse and AGS neural progenitor cells (NPCs), expression of ATP5G3 or ATP5G2 is greater than that of ATP5G1, consistent with patterns observed in human and mouse tissues .

• The relative abundance of the ATP5G1 isoform is elevated nearly twofold in AGS NPCs compared to mouse NPCs .

• Despite differences in isoform expression levels, the relative abundance of mature ATP5G (subunit C) protein and oligomycin sensitivity of complex V activity does not differ significantly between mouse and AGS cells .

This differential regulation suggests that:

• Isoform-specific primers must be designed for qRT-PCR to accurately distinguish between ATP5G1, ATP5G2, and ATP5G3 transcripts

• Protein-level studies may not reflect transcript-level differences due to post-transcriptional regulation

• Functional studies should consider compensatory mechanisms between isoforms

How can researchers distinguish between the processing of ATP5G1 and its mature form in experimental systems?

Distinguishing between ATP5G1 precursor and its mature processed form requires specific methodological approaches:

• Subcellular fractionation: Separate mitochondrial fractions from cytosolic fractions using differential centrifugation protocols.

• Size discrimination: The precursor form contains the mitochondrial targeting sequence and will appear at a higher molecular weight than the processed mature form.

• Selective antibodies: Use antibodies that specifically target:

  • The N-terminal region (detecting primarily the precursor form)

  • The mature protein region (detecting the processed form)

• Import inhibition experiments: Treatment with mitochondrial import inhibitors can help distinguish between newly synthesized and mature forms.

Importantly, when studying variants like the AGS ATP5G1, researchers should note that amino acid substitutions do not alter mitochondrial localization of ATP5G1 when expressed in either mouse or AGS NPCs , suggesting proper import and processing despite sequence differences.

What experimental approaches can accurately measure ATP5G1-dependent ATP synthase activity?

To measure ATP5G1-dependent ATP synthase activity:

• Oligomycin sensitivity assay: Measures ATP synthase activity by determining sensitivity to the inhibitor oligomycin. Studies show that despite differences in ATP5G1 sequence between species, oligomycin sensitivity of complex V activity is not significantly different in mouse and AGS cells .

• Oxygen consumption rate (OCR) measurements: Using platforms like Seahorse XF analyzers to measure:

  • Basal respiration

  • ATP-linked respiration

  • Maximal respiration

  • Spare respiratory capacity

• Mitochondrial membrane potential assays: Using fluorescent probes like TMRM or JC-1 to assess the proton gradient that drives ATP synthesis.

• ATP production assays: Direct measurement of ATP levels using luminescent assays.

When comparing wild-type versus variant forms of ATP5G1, researchers should assess multiple parameters as AGS ATP5G1 variants demonstrate altered spare respiratory capacity but may affect other aspects of mitochondrial function through different mechanisms .

How does the Arctic ground squirrel (AGS) variant of ATP5G1 confer cytoprotection against metabolic stress?

The AGS variant of ATP5G1 has been identified as a critical factor in metabolic stress resilience through several mechanisms:

• Amino acid substitution: The L32P substitution in AGS ATP5G1 has been causally linked to cytoprotection against hypoxia, hypothermia, and rotenone exposure . This single amino acid change occurs in the N-terminal region of ATP5G1, which is normally variable among species, while the C-terminal membrane-spanning segment remains largely invariant .

• Mitochondrial morphology regulation: The AGS variant promotes:

  • Reduced mitochondrial fission in response to stressors like FCCP

  • Increased mitochondrial branch length

  • Reduced mitochondrial fragmentation

• Bioenergetic enhancements: AGS ATP5G1 increases spare respiratory capacity, enhancing the cells' ability to respond to increased energy demands during stress .

• Experimental validation: When the AGS ATP5G1 variant was introduced into mouse neural progenitor cells (NPCs), it conferred significant protection against multiple metabolic stressors . Conversely, when AGS ATP5G1 was modified to contain the mouse/human version of the amino acid (P32L mutation), the protective effects were reduced .

Methodologically, researchers investigating similar protective genetic variants should employ multiple stress conditions (as done with hypoxia, hypothermia, and rotenone) to identify consistently protective factors rather than stress-specific responses .

What CRISPR-based approaches are most effective for studying ATP5G1 variants?

CRISPR-based approaches offer powerful tools for studying ATP5G1 variants:

• Base editing technology: The dCas9 adenine base editor (ABE) technology has been successfully used to validate the unique AGS ATP5G1 L32P variant . This technique allows for precise single nucleotide changes without double-strand breaks.

• Knock-in strategy: For studying the functional effects of specific amino acid substitutions like the L32P variant, CRISPR knock-in approaches can introduce the desired mutation into endogenous loci.

• Validation approaches: When using CRISPR to modify ATP5G1:

  • Confirm editing efficiency through sequencing

  • Verify that mitochondrial localization is maintained

  • Assess functional consequences through multiple assays (survival, mitochondrial morphology, respiratory capacity)

• Controls: Include appropriate controls:

  • Wild-type cells

  • Cells with synonymous mutations (same amino acid, different codon)

  • Cells with other amino acid substitutions at the same position

Importantly, CRISPR-edited ATP5G1 L32P knock-in (KI) cells demonstrate improved survival under metabolic stress conditions compared to control cells, confirming the causal role of this specific amino acid substitution in cytoprotection .

How do different ATP5G1 variants affect mitochondrial dynamics and what methodologies best capture these differences?

ATP5G1 variants significantly impact mitochondrial dynamics, with distinct methodological approaches required to properly characterize these effects:

• Mitochondrial morphology analysis:

  • AGS ATP5G1 reduces mitochondrial fission and fragmentation in response to stressors like FCCP

  • AGS ATP5G1 increases mitochondrial branch length

  • These effects are diminished when the L32P residue is mutated to P32L (the mouse/human version)

• Quantitative parameters to measure:

  • Form factor (a measure of mitochondrial branching)

  • Aspect ratio (length-to-width ratio)

  • Mean branch length

  • Fragmentation index (number of separate mitochondrial particles)

• Live-cell imaging approaches:

  • Fluorescent mitochondrial markers (MitoTracker, mitochondria-targeted fluorescent proteins)

  • Time-lapse microscopy to track dynamic changes

  • Photoactivatable fluorescent proteins to track specific mitochondrial subpopulations

• Bioenergetic profiling:

  • AGS ATP5G1 increases spare respiratory capacity

  • This effect is partially lost with the P32L mutation

When designing studies of mitochondrial dynamics, researchers should include both baseline measurements and stress-induced responses, as variant-dependent differences may only become apparent under metabolic stress conditions .

How is ATP5G1 expression altered in disease states and what are the implications for therapeutic targeting?

ATP5G1 expression shows significant alterations in disease states based on transcriptomic analyses:

This data reveals:

• Substantial downregulation: ATP5G1 shows the most dramatic downregulation among ATP synthase components in disease states, with fold changes of -8.09 and -5.88 in screening and validation cohorts, respectively .

• Differential regulation: The magnitude of ATP5G1 downregulation exceeds that of other ATP synthase subunits, suggesting potential specific regulatory mechanisms or functional consequences .

• Therapeutic implications:

  • ATP5G1's dramatic reduction suggests it could serve as a disease biomarker

  • The cytoprotective properties of specific ATP5G1 variants like the AGS L32P variant offer potential therapeutic strategies

  • Restoring ATP5G1 function or expression might counteract disease progression

Methodologically, researchers investigating ATP5G1 in disease contexts should:

• Include multiple control and disease samples

• Consider cell-type specific expression patterns

• Validate transcriptomic findings at the protein level

• Assess functional consequences of altered expression

What is the relationship between ATP5G1 and mitochondrial spare respiratory capacity, and how can this be experimentally manipulated?

Spare respiratory capacity (SRC) represents the difference between basal and maximal mitochondrial respiration and is a key indicator of cellular resilience to stress:

• ATP5G1 variant effects on SRC:

  • The AGS variant of ATP5G1 increases spare respiratory capacity in neural progenitor cells

  • This enhanced SRC correlates with improved survival under metabolic stress conditions

  • When the critical L32P residue is mutated to the mouse/human version (P32L), the SRC enhancement is reduced

• Experimental manipulation approaches:

  • Genetic: Overexpression of wild-type or variant ATP5G1

  • CRISPR: Base editing to introduce specific amino acid changes

  • Pharmacological: Modulators of ATP synthase activity or assembly

• Measurement methodologies:

  • Oxygen consumption rate (OCR) using platforms like Seahorse XF analyzers

  • Sequential addition of oligomycin (ATP synthase inhibitor), FCCP (uncoupler), and rotenone/antimycin A (electron transport chain inhibitors)

  • Calculation: Maximal OCR minus Basal OCR equals SRC

• Interpretative considerations:

  • Interestingly, human ATP5G1 with the L32P modification improves survival to metabolic stressors but does not significantly improve spare respiratory capacity compared to AGS ATP5G1 with P32L mutation

  • This suggests that improving spare respiratory capacity itself is not the sole mechanism conferring resilience to metabolic stressors

Researchers should include multiple functional readouts beyond SRC when assessing ATP5G1 variants, as the relationship between SRC and stress resistance appears complex and potentially multifactorial.

How do post-translational modifications affect ATP5G1 function and how can these be detected in experimental systems?

While the search results don't specifically address post-translational modifications (PTMs) of ATP5G1, researchers investigating this aspect should consider:

• Potential PTM types affecting ATP5G1:

  • Phosphorylation: May regulate activity or interactions

  • Acetylation: Could affect mitochondrial protein stability

  • Ubiquitination: Potentially regulating protein turnover

• Detection methodologies:

  • Mass spectrometry-based proteomics for unbiased PTM identification

  • Phospho-specific or acetylation-specific antibodies

  • Mobility shift assays to detect modified forms

• Functional assessment approaches:

  • Site-directed mutagenesis of potential PTM sites

  • Inhibitors of specific modifying enzymes

  • In vitro enzymatic assays with purified ATP5G1

• Stress-induced modifications:

  • Given ATP5G1's role in stress responses, PTMs may be differentially regulated under metabolic stress conditions

  • Comparison between normal and stress conditions could reveal regulatory PTMs

• Species-specific considerations:

  • The N-terminal region of ATP5G1 shows variability between species, including the critical L32P substitution in AGS

  • This region may also contain species-specific PTM sites that contribute to functional differences

Researchers should consider that the processing of ATP5G1 includes removal of the mitochondrial targeting sequence upon import, which affects which PTM sites remain in the mature protein.

What are the most promising therapeutic applications of ATP5G1 research?

The study of ATP5G1, particularly the cytoprotective AGS variant, suggests several promising therapeutic directions:

• Ischemia-reperfusion injury protection:

  • The AGS ATP5G1 variant confers protection against hypoxia, suggesting potential applications in stroke, heart attack, and transplantation medicine

  • Gene therapy approaches could deliver the protective variant to vulnerable tissues

• Neurodegenerative disease applications:

  • Mitochondrial dysfunction is implicated in many neurodegenerative diseases

  • ATP5G1 variants that enhance mitochondrial resilience could potentially slow disease progression

• Drug development strategies:

  • Small molecules that mimic the effects of the AGS L32P substitution

  • Compounds that modulate ATP5G1 function or stability

  • Peptide-based therapeutics targeting ATP5G1 interactions

• CRISPR-based therapeutic approaches:

  • The successful use of base editing to introduce the L32P substitution suggests potential for therapeutic editing

  • Systematic investigation of additional cytoprotective genes and amino acid substitutions identified from AGS should provide important insights into mechanisms underlying intrinsic stress resilience

As noted in the research: "Further unraveling of the mechanisms underlying AGS mitochondrial and cellular resilience to metabolic stress or injuries holds the hope of finding novel cytoprotective strategies that may lead to improved treatments for human diseases" .

What experimental models are most appropriate for studying ATP5G1 function in different physiological contexts?

Researchers should consider these experimental models when studying ATP5G1:

• Cellular models:

  • Neural progenitor cells (NPCs): Successfully used to demonstrate ATP5G1 variant effects

  • Primary cells from tissues with high metabolic demands (cardiomyocytes, neurons)

  • Cell lines engineered with CRISPR to express ATP5G1 variants

• Organoid models:

  • Brain organoids for neurodevelopmental and neuroprotection studies

  • Cardiac organoids for ischemia-reperfusion modeling

• Animal models:

  • Hibernating species comparative studies (e.g., Arctic ground squirrel)

  • Transgenic mice expressing ATP5G1 variants

  • CRISPR-engineered animal models with specific ATP5G1 amino acid substitutions

• Disease-specific models:

  • Ischemia-reperfusion injury models

  • Neurodegenerative disease models

  • Metabolic stress models (hypoxia, hypothermia, toxin exposure)

• Methodological considerations:

  • Include appropriate controls (species-matched, stress conditions)

  • Validate findings across multiple model systems

  • Consider tissue-specific expression patterns of ATP5G isoforms

The choice of model should be guided by the specific research question, with consideration of the differential expression of ATP5G isoforms across tissues and species.

How might combining ATP5G1 research with other mitochondrial targets enhance our understanding of metabolic resilience mechanisms?

An integrated approach to studying ATP5G1 alongside other mitochondrial components would provide deeper insights into metabolic resilience:

• Comprehensive mitochondrial protein analysis:

  • Investigate interactions between ATP5G1 and other ATP synthase subunits

  • Examine how ATP5G1 variants affect assembly and stability of the entire complex

  • Study potential compensatory mechanisms involving ATP5G2 and ATP5G3

• Mitochondrial dynamics pathways:

  • Explore interactions between ATP5G1 and mitochondrial fission/fusion proteins

  • Investigate how ATP5G1 variants affect mitochondrial quality control mechanisms

  • Study potential cross-talk with mitophagy pathways

• Metabolic adaptation networks:

  • Combine ATP5G1 research with studies of metabolic sensors (AMPK, mTOR)

  • Investigate interactions with hypoxia response pathways (HIF-1α)

  • Examine crosstalk with antioxidant defense systems

• Multi-omics approaches:

  • Integrate proteomic, metabolomic, and transcriptomic analyses

  • Identify metabolic signatures associated with ATP5G1 variants

  • Map broader network effects of ATP5G1 modifications

As the research suggests, the AGS ATP5G1 variant alone does not fully recapitulate the resilience phenotype of AGS cells , indicating that "variants of other genes and proteins may also be involved in providing protection" . Systematic investigation of additional cytoprotective genes identified from AGS models would provide important insights into the mechanisms underlying intrinsic stress resilience .